不可预后不良前列腺肿瘤的消融放疗(ABRUPT):前瞻性研究的毒性与生活质量初步分析
这项单臂前瞻性研究纳入30例器官局限预后不良前列腺癌患者,接受24 Gy单次消融放疗(全腺体照射、保留尿道、器官运动控制),联合雄激素剥夺治疗和预防用药。中位随访18个月,未观察到≥G3晚期毒性,仅1例G2晚期胃肠道毒性和2例G2晚期泌尿生殖毒性。泌尿域生活质量评分中位从8升至17(P=0.005),急性泌尿域最小重要差异可预测晚期泌尿域最小重要差异(OR 9.7,P=0.035)。
要点
- 30例器官局限预后不良前列腺癌接受24 Gy单次消融放疗,中位随访18个月,无≥G3晚期毒性。
- 晚期G2胃肠道毒性和G2泌尿生殖毒性分别仅1例和2例。
- 仅泌尿域生活质量出现显著变化,中位评分从8升至17。
核心结论
- 研究结果初步提示,在器官局限预后不良前列腺癌中,24 Gy全腺体单次消融放疗联合保留尿道、器官运动控制、雄激素剥夺治疗和充分预防用药具有可行性和安全性。
- 需要长期随访来证实这些结果。
研究设计与样本
- 单臂前瞻性试验,纳入30例器官局限预后不良前列腺癌患者。
- 患者接受24 Gy单次消融放疗照射全前列腺,保留尿道并控制器官运动,在配有10 MV无均整滤波器的直线加速器平台上采用单部分弧照射。
- 按标准治疗给予雄激素剥夺治疗。
- 在不同时间点评估治疗相关急性和晚期泌尿生殖及胃肠道毒性(常见不良事件评价标准第5版)和生活质量(欧洲癌症研究与治疗组织QLQ-PR25/C30量表、国际前列腺症状评分)。
主要发现
- 中位随访18个月(范围6至31个月),未观察到≥G3晚期副作用。
- 晚期G2胃肠道毒性和晚期G2泌尿生殖毒性分别发生于1例和2例患者。
- 任何级别胃肠道毒性与最大直肠剂量相关(P=0.021)。
- 单因素分析中,较低基线生活质量评分(P=0.025)、较高基线国际前列腺症状评分(P=0.049)、急性泌尿生殖毒性(P=0.029)和急性泌尿域最小重要差异(P=0.045)预测任何级别泌尿生殖毒性。
- 多因素分析中,仅基线生活质量评分(OR 0.95,P=0.031)和急性泌尿生殖毒性(OR 8.4,P=0.041)保持显著。
局限性
- 中位随访仅18个月(范围6至31个月),需要长期随访来证实这些结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess late gastrointestinal (GI) and genitourinary (GU) side effects in patients with organ-confined unfavorable prostate cancer (PCa) treated with single-dose ablative radiation therapy (SDRT). METHODS AND MATERIALS: Thirty patients enrolled in a single-arm prospective trial received 24 Gy SDRT to the whole prostate with urethra-sparing and organ motion control delivered on a Linac platform with a 10 MV flattening filter-free single partial arc. Androgen deprivation therapy was prescribed as per standard of care. Treatment-related acute and late GU and GI toxicities (Common Terminology Criteria for Adverse Events_v5 scale) and quality of life (QoL) outcomes (European Organisation for Research and Treatment of Cancer [EORTC] QLQ-PR25/C30, International Prostate Symptom Score [IPSS]) were assessed at different time points. Minimal important difference (MID) was established as a change of >0.5 pooled standard deviations from baseline. Statistical analysis included analysis of variance and logistic regression. RESULTS: Median follow-up was 18 months (range, 6-31 months), with no ≥G3 late side effects observed. G2 late GI and G2 late GU toxicities occurred in 1 and 2 patients, respectively. GI toxicity of any grade correlated with maximum rectal dose (P = .021). Lower baseline QoL score (P = .025), higher baseline IPSS score (P = .049), acute GU toxicity (P = .029), and acute urinary domain MID (P = .045) predicted GU toxicity of any grade. In multivariate analysis (MVA), only baseline QoL score (odds ratio [OR], 0.95, P = .031) and acute GU toxicity (OR, 8.4, P = .041) remained significant. Significant QoL change was observed only in the urinary domain (P = .005), with a median increase from 8 to 17. Late urinary MID correlated with acute urinary MID (P = .003), acute QoL MID (P = .029), acute GU toxicity (P = .030), and lower baseline urinary score (P = .033). In MVA, only acute urinary MID predicted late urinary MID (OR, 9.7, P = .035). CONCLUSIONS: Our findings provide promising data on the feasibility and safety of 24 Gy whole-gland SDRT with urethra-sparing and organ motion control, in association with androgen deprivation therapy and an adequate prophylactic medication, in organ-confined unfavorable PCa. Long-term follow-up is needed to confirm these results.
引用
- Arcangeli S, Chissotti C, Ferrario F, et al. Ablative Radiation Therapy for Unfavorable Prostate Tumors (ABRUPT): Preliminary Analysis of Toxicity and Quality of Life from a Prospective Study. Int J Radiat Oncol Biol Phys. 2024. PMID: 38971384. doi:10.1016/j.ijrobp.2024.06.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。